Pan-serotype Reduction in Progression of Streptococcus pneumoniae to Otitis Media after Rollout of Pneumococcal Conjugate Vaccines

Clinical Infectious Diseases

Volumn 65, Issue 11, 2017, Pages 1853-1861

  Lewnard, Joseph A ^a   Givon Lavi, Noga ^b,c   Weinberger, Daniel M ^d   Lipsitch, Marc ^a   Dagan, Ron ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Soroka University Medical Center   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d YALE UNIVERSITY   (United States)

Author keywords

complex otitis media; otitis media; pneumococcal conjugate vaccine; surveillance

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE; VACCINE;

ARTICLE; BEDOUIN; CHILD; CROWDING (AREA); DISEASE COURSE; HUMAN; JEW; MIDDLE EAR; OTITIS MEDIA; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SOCIAL STATUS; STREPTOCOCCUS PNEUMONIAE; ARAB; BAYES THEOREM; DISEASE EXACERBATION; FEMALE; HEALTH SURVEY; HETEROZYGOTE; IMMUNOLOGY; INCIDENCE; INFANT; ISOLATION AND PURIFICATION; ISRAEL; MALE; MICROBIOLOGY; NASOPHARYNX; PHYSIOLOGY; PRESCHOOL CHILD; PREVALENCE; PROSPECTIVE STUDY; SEROTYPE;

ARABS; BAYES THEOREM; CARRIER STATE; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; INCIDENCE; INFANT; ISRAEL; MALE; NASOPHARYNX; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; PREVALENCE; PROSPECTIVE STUDIES; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 85034813468     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix673     Document Type: Article

References (40)

1. Rovers MM. The burden of otitis media. Vaccine 2008; 26 Suppl 7:G2-4.
2. Dagan R, Pelton S, Bakaletz L, Cohen R. Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease. Lancet Infect Dis 2016; 16:480-92.
3. Luotonen J, Herva E, Karma P, Timonen M, Leinonen M, Mäkelä PH. The bacteriology of acute otitis media in children with special reference to Streptococcus pneumoniae as studied by bacteriological and antigen detection methods. Scand J Infect Dis 1981; 13:177-83.
4. Del Beccaro MA, Mendelman PM, Inglis AF, et al. Bacteriology of acute otitis media: a new perspective. J Pediatr 1992; 120:81-4.
5. Flasche S, van Hoek AJ, Sheasby E, et al. Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study. PLoS Med 2011; 8:e14.
6. Fortanier AC, Venekamp RP, Boonacker CWB, et al. Pneumococcal conjugate vaccines for preventing otitis media. Cochrane database Syst Rev 2014; 4:CD001480.
7. Gisselsson-Solén M, Melhus A, Hermansson A. Pneumococcal vaccination in children at risk of developing recurrent acute otitis media-a randomized study. Acta Paediatr 2011; 100:1354-8.
8. Sarasoja I, Jokinen J, Lahdenkari M, Kilpi T, Palmu AA. Long-term effect of pneumococcal conjugate vaccines on tympanostomy tube placements. Pediatr Infect Dis J 2013; 32:517-20.
9. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006; 367:740-8.
10. O'Brien KL, David AB, Chandran A, et al. Randomized, controlled trial efficacy of pneumococcal conjugate vaccine against otitis media among Navajo and White Mountain Apache infants. Pediatr Infect Dis J 2008; 27:71-3.
11. Rodriguez WJ, Schwartz RH. Streptococcus pneumoniae causes otitis media with higher fever and more redness of tympanic membranes than Haemophilus influenzae or Moraxella catarrhalis. Pediatr Infect Dis J 1999; 18:942-4.
12. Polachek A, Greenberg D, Lavi-Givon N, et al. Relationship among peripheral leukocyte counts, etiologic agents and clinical manifestations in acute otitis media. Pediatr Infect Dis J 2004; 23:406-13.
13. Dagan R, Leibovitz E, Greenberg D, Bakaletz L, Givon-Lavi N. Mixed pneumococcal-nontypeable Haemophilus influenzae otitis media is a distinct clinical entity with unique epidemiologic characteristics and pneumococcal serotype distribution. J Infect Dis 2013; 208:1152-60.
14. Taylor S, Marchisio P, Vergison A, Harriague J, Hausdorff WP, Haggard M. Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis 2012; 54:1765-73.
15. Caeymaex L, Varon E, Levy C, et al. Characteristics and outcomes of acute otitis media in children carrying Streptococcus pneumoniae or Haemophilus influenzae in their nasopharynx as a single otopathogen after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2014; 33:533-6.
16. Ben-Shimol S, Givon-Lavi N, Leibovitz E, Raiz S, Greenberg D, Dagan R. Impact of widespread introduction of pneumococcal conjugate vaccines on pneumococcal and nonpneumococcal otitis media. Clin Infect Dis 2016; 63:611-8.
17. Tregnaghi MW, Sáez-Llorens X, López P, et al.; COMPAS Group. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med 2014; 11:e1001657.
18. Flasche S, Givon-Lavi N, Dagan R. Using pneumococcal carriage data to monitor postvaccination changes in the incidence of pneumococcal otitis media. Am J Epidemiol 2016; 184:652-9.
19. Marom T, Tan A, Wilkinson GS, Pierson KS, Freeman JL, Chonmaitree T. Trends in otitis media-related health care use in the United States, 2001-2011. JAMA Pediatr 2014; 168:68-75.
20. Poehling KA, Szilagyi PG, Grijalva CG, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 2007; 119:707-15.
21. Wals PD, Carbon M, Sévin E, Deceuninck G, Ouakki M. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 2009; 28:e271-5.
22. Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 2008; 121:253-60.
23. Israel Central Bureau of Statistics. Statistical Abstract of Israel No. 67, 2016.
24. Ben-Shimol S, Givon-Lavi N, Greenberg D, Dagan R. Pneumococcal nasopharyngeal carriage in children 5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel. Hum Vaccin Immunother 2016; 12:268-76.
25. Dagan R, Amir J, Livni G, et al. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr Infect Dis J 2007; 26:787-93.
26. Lewnard JA, Givon-Lavi N, Huppert A, et al. Epidemiological markers for interactions among Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus in upper respiratory tract carriage. J Infect Dis 2016; 213:1596-605.
27. Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44:43-50.
28. Weinberger DM, Trzciński K, Lu YJ, et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog 2009; 5:e1000476.
29. Li Y, Weinberger DM, Thompson CM, Trzciński K, Lipsitch M. Surface charge of Streptococcus pneumoniae predicts serotype distribution. Infect Immun 2013; 81:4519-24.
30. Sleeman KL, Griffiths D, Shackley F, et al. Capsular serotype-specific attack rates and duration of carriage of Streptococcus pneumoniae in a population of children. J Infect Dis 2006; 194:682-8.
31. Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med 2009; 6:e1000081.
32. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1-35.
33. Howie VM, Ploussard JH, Sloyer J. The "otitis-prone" condition. Am J Dis Child 1975; 129:676-8.
34. Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989; 160:83-94.
35. Guan X, Jiang S, Seale TW, Hitt BM, Gan RZ. Morphological changes in the tympanic membrane associated with Haemophilus influenzae-induced acute otitis media in the chinchilla. Int J Pediatr Otorhinolaryngol 2015; 79:1462-71.
36. Juhn SK, Tsuprun V, Lee Y-W, Hunter B, Schachern P. Interaction between middle and inner ears in otitis media. Audiol Med 2004; 2:158-61.
37. Nzenze SA, Shiri T, Nunes MC, et al. Temporal changes in pneumococcal colonization in a rural African community with high HIV prevalence following routine infant pneumococcal immunization. Pediatr Infect Dis J 2013; 32:1270-8.
38. Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health 2014; 2:e397-405.
39. Shouval DS, Greenberg D, Givon-Lavi N, Porat N, Dagan R. Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease, acute otitis media and acute conjunctivitis. Pediatr Infect Dis J 2006; 25:602-7.
40. Lewnard JA, Huppert A, Givon-Lavi N, et al. Density, serotype diversity, and fitness of Streptococcus pneumoniae in upper respiratory tract cocolonization with nontypeable Haemophilus influenzae. J Infect Dis 2016; 214:1411-20.